Observational studyThe Journal of pediatrics2022
Bifidobacteriumlongum subsp. infantis EVC001 Administration Is Associated with a Significant Reduction in the Incidence of Necrotizing Enterocolitis in Very Low Birth Weight Infants.
Observational study in The Journal of pediatrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Bifidobacterium infantis as a probiotic in preterm infants: a systematic review and meta-analysis.Pediatric research · 2023Pooled it
- Early Probiotic Supplementation of Healthy Term Infants withNutrients · 2023Trial
- PROTECT-Preterm: emulating target trials of dynamic probiotic strategies for necrotising enterocolitis, late-onset sepsis and mortality in very preterm infants - a study protocol.BMJ paediatrics open · 2026Article
- Effect of Probiotics on the Gut-Mammary Pathway: Implications on Infant Microbiota Transfer and Development.Current nutrition reports · 2026Review
- Gut-microbiota-derived 3-indoleacrylic acid alleviates neonatal necrotizing enterocolitis by inhibiting epithelial necroptosis.Cell reports. Medicine · 2026Article
- A Review of Probiotic Interventions for Necrotizing Enterocolitis and Sepsis in Preterm Infants.International journal of molecular sciences · 2026Review
- Metagenomic strain tracking reveals patterns of bacterial spread and the impact of water chlorination.medRxiv : the preprint server for health sciences · 2026Article
- Mechanisms by which tryptophan metabolites enhance intestinal barrier function to prevent necrotizing enterocolitis in preterm infants.Frontiers in immunology · 2026Review
- The microbiome's hidden influence: preclinical insights into inflammatory responses in necrotizing enterocolitis.Seminars in immunopathology · 2025Review
- Bifidobacterium longum subsp infantis (EVC001) is associated with reduced incidence of necrotizing enterocolitis stage ≥2 and bloody stools in premature babies.Journal of perinatology : official journal of the California Perinatal Association · 2025Article
- Review
- Contemporary use of prophylactic probiotics in NICUs in the United States: a survey update.Journal of perinatology : official journal of the California Perinatal Association · 2024Article
- The Genome ofGenes · 2024Article
- Probiotics and Human Milk Differentially Influence the Gut Microbiome and NEC Incidence in Preterm Pigs.Nutrients · 2023Article
- Intravenous antibiotics in preterm infants have a negative effect upon microbiome development throughout preterm life.Gut pathogens · 2023Article
- Probiotics for prevention of necrotizing enterocolitis: Where do we stand?Seminars in perinatology · 2023Review
- Shaping infant development from the inside out: Bioactive factors in human milk.Seminars in perinatology · 2023Review
- Gut microbiome and breast-feeding: Implications for early immune development.The Journal of allergy and clinical immunology · 2022Review
- Microbiome-based interventions to modulate gut ecology and the immune system.Mucosal immunology · 2022Review
- Milk: A Scientific Model for Diet and Health Research in the 21st Century.Frontiers in nutrition · 2022Review
Corrections and comments
- Commented on by
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveTo assess the effects of Bifidobacteriumlongum subsp. infantis EVC001 (Binfantis EVC001) administration on the incidence of necrotizing enterocolitis (NEC) in preterm infants in a single level IV neonatal intensive care unit (NICU). STUDY
designNonconcurrent retrospective analysis of 2 cohorts of very low birth weight (VLBW) infants not exposed and exposed to Binfantis EVC001 probiotic at Oregon Health & Science University from 2014 to 2020. Outcomes included NEC incidence and NEC-associated mortality, including subgroup analysis of extremely low birth weight (ELBW) infants. Log-binomial regression models were used to compare the incidence and risk of NEC-associated outcomes between the unexposed and exposed cohorts.
resultsThe cumulative incidence of NEC diagnoses decreased from 11.0% (n = 301) in the no EVC001 (unexposed) cohort to 2.7% (n = 182) in the EVC001 (exposed) cohort (P < .01). The EVC001 cohort had a 73% risk reduction of NEC compared with the no EVC001 cohort (adjusted risk ratio, 0.27; 95% CI, 0.094-0.614; P < .01) resulting in an adjusted number needed to treat of 13 (95% CI, 10.0-23.5) for Binfantis EVC001. NEC-associated mortality decreased from 2.7% in the no EVC001 cohort to 0% in the EVC001 cohort (P = .03). There were similar reductions in NEC incidence and risk for ELBW infants (19.2% vs 5.3% [P < .01]; adjusted risk ratio, 0.28; 95% CI, 0.085-0.698 [P = .02]) and mortality (5.6% vs 0%; P < .05) in the 2 cohorts.
conclusionsIn this observational study of 483 VLBW infants, Binfantis EVC001 administration was associated with significant reductions in the risk of NEC and NEC-related mortality. Binfantis EVC001 supplementation may be considered safe and effective for reducing morbidity and mortality in the NICU.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.